Jerill Thorpe

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

S. Alice Long, Jerill Thorpe, Hannah A. DeBerg et al. · Science Immunology · 2016 · 241 citations · Full text

Clinical Immunology, T-regulatory Cell, Immunology +17

Comparison of commercial kits for detection of cryptococcal antigen

David C. Tanner, Melvin P. Weinstein, B Fedorciw et al. · Journal of Clinical Microbiology · 1994 · 238 citations · Full text

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · The Lancet Oncology · 2022 · 217 citations

Hematological Malignancy, Lymphoid Neoplasia, Transplantation +10

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen Dorritie et al. · Blood · 2021 · 116 citations · Full text

Immunology, Prior Therapies, Pathology +20

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes

S. Alice Long, Jerill Thorpe, Kevan C. Herold et al. · Cellular Immunology · 2017 · 82 citations · Full text